Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy
Sponsor: Daiichi Sankyo
This PHASE3 trial investigates Essential Hypertension and is currently completed. Daiichi Sankyo leads this study, which shows 13 recorded versions since 2007 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Mar 2024 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Completed PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
For direct contact, visit the study record on ClinicalTrials.gov .